Despite the fact that CRISP3 expression has been linked to the genesis and progression of prostate and breast malignancies (Wang et al., 2019; Volpert et al., 2020), CRISP3 exhibited non-significant expression in pan-cancer tissues (Supplementary Figure S1), and ADH1B has been verified in cancer (Li et al., 2017); therefore, CLU was selected. The gene discussed is ADH1B; the disease is cancer.